Aromatase as a therapeutic target in endometriosis

Serdar E. Bulun, Khaled M. Zeitoun, Kazuto Takayama, Evan Simpson, Hironobu Sasano

Research output: Contribution to journalReview articlepeer-review

50 Citations (Scopus)


In contrast to normal endometrium, the expression of aromatase is aberrant in endometriosis and is stimulated by prostaglandin E2 (PGE2). This results in local production of estrogen, which induces PGE2 formation and establishes a positive feedback cycle. Another abnormality in endometriosis - deficient 17β-hydroxysteroid dehydrogenase (17β-HSD) type 2 expression - impairs the inactivation of estradiol (E2) to estrone (E1). These molecular aberrations collectively favor accumulation of increasing quantities of E2 and PGE2 in endometriosis. The clinical relevance of these findings was exemplified by the successful treatment of an unusually aggressive case of postmenopausal endometriosis with an aromatase inhibitor.

Original languageEnglish
Pages (from-to)22-27
Number of pages6
JournalTrends in Endocrinology and Metabolism
Issue number1
Publication statusPublished - 2000 Feb 1
Externally publishedYes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'Aromatase as a therapeutic target in endometriosis'. Together they form a unique fingerprint.

Cite this